Baker Bros. Advisors’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-3,009,344
| Closed | -$410M | – | 132 |
|
|
2020
Q3 | $410M | Sell |
3,009,344
-154,890
| -5% | -$16.5M | 1.64% | 10 |
|
|
2020
Q2 | $306M | Buy |
3,164,234
+1,390,000
| +78% | +$116M | 1.35% | 10 |
|
|
2020
Q1 | $83.2M | Hold |
1,774,234
| – | – | 0.51% | 19 |
|
|
2019
Q4 | $129M | Buy |
1,774,234
+256,997
| +17% | +$15.6M | 0.69% | 17 |
|
|
2019
Q3 | $79.1M | Buy |
1,517,237
+500,931
| +49% | +$26.6M | 0.54% | 17 |
|
|
2019
Q2 | $51M | Hold |
1,016,306
| – | – | 0.35% | 30 |
|
|
2019
Q1 | $52.8M | Buy |
1,016,306
+701,063
| +222% | +$32.3M | 0.34% | 31 |
|
|
2018
Q4 | $15.4M | Sell |
315,243
-41,972
| -12% | -$2.31M | 0.13% | 40 |
|
|
2018
Q3 | $23.3M | Sell |
357,215
-75,906
| -18% | -$4.46M | 0.15% | 37 |
|
|
2018
Q2 | $21.5M | Buy |
433,121
+142,857
| +49% | +$6.92M | 0.16% | 40 |
|
|
2018
Q1 | $14.2M | Sell |
290,264
-65,000
| -18% | -$3.38M | 0.12% | 47 |
|
|
2017
Q4 | $15M | Hold |
355,264
| – | – | 0.13% | 50 |
|
|
2017
Q3 | $15.2M | Buy |
355,264
+255,264
| +255% | +$8.14M | 0.12% | 44 |
|
|
2017
Q2 | $1.31M | Hold |
100,000
| – | – | 0.01% | 97 |
|
|
2017
Q1 | $1.31M | Hold |
100,000
| – | – | 0.01% | 97 |
|
|
2016
Q4 | $1.29M | Hold |
100,000
| – | – | 0.01% | 101 |
|
|
2016
Q3 | $1.63M | Buy |
+100,000
| New | +$1.81M | 0.01% | 102 |
|
Baker Bros. Advisors's MYOK Position: Q4 2020 in Review
Baker Bros. Advisors sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 3,009,344 shares — an estimated $410M sold.
Baker Bros. Advisors first reported a position in MYOK in Q3 2016 and held it in 17 quarters. The position peaked at $410M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Baker Bros. Advisors reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Baker Bros. Advisors sold 3,009,344 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $410M.
- Baker Bros. Advisors first reported a position in MyoKardia, Inc. Common Stock in Q3 2016 and held it in 17 quarters.
- Baker Bros. Advisors's MyoKardia, Inc. Common Stock position peaked at $410M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.